JP2021526067A - Pharmaceutical case - Google Patents

Abstract

The present invention is a drug case (1), and its use, which is designed to contain a removable blister pack (2) that houses a series of drugs (3) and is equipped with an electronic monitoring device (13). Regarding.

Description

The present invention relates to a drug case, more particularly to a drug case designed to contain a removable blister pack equipped with an electronic monitoring device, and to patient compliance with a prescribed dose. Regarding its use to determine.

Patient compliance with dosing plans is of increasing interest today. The dosing regimen of a drug prescribed to a patient, also called the dose, is defined by both the recommended dose and the frequency of dosing. When the drug is taken, the active substance is metabolized and absorbed by the patient, its plasma concentration increases and then decreases over time. The dosing regimen aims to maintain plasma concentrations within the therapeutic range, i.e., within the concentration range that ensures optimal therapeutic effect while minimizing the risk of adverse effects. It aims to not fall below the minimum concentration equivalent to underdose to the patient, which leads to an increased risk of treatment failure, and not to exceed the maximum concentration corresponding to overdose to the patient, leading to an increased risk of toxicity. And. In this regard, delayed release or sustained release therapies have been developed.

The frequency with which a patient takes a drug, and thus compliance with the dosing regimen prescribed to the patient, depends on a number of factors, both intentional and unintentional (forgetting). In addition, if side effects occur, the patient's hesitation to take the prescribed dose is for comfort reasons such that the side effects are intended to be taken at a more appropriate time or place. , May result in delaying any one of the doses.

Therefore, pharmaceutical cases including electronic devices have been developed.

Therefore, pharmaceutical cases with electronic devices are known from the art, such as those used to measure the exact time when a drug is taken by a patient, which can be compared to a prescribed dosing regimen. .. This measurement of variability between the patient's expected and measured behaviors may be useful to healthcare professionals to better monitor the patient. It is also common practice to use a reminder device integrated with the case with or without these electronic devices to measure the exact time of dosing, and these reminder devices are simply It may or may not be integrated with these dosing measuring devices to form a single entity. For example, it is common for patients to use pre-programmed electronic reminder devices for doses prescribed by their physician. The electronic device emits, for example, an audible or light-based warning signal to inform the patient that the patient must take the drug. The reminder device may be, for example, a smartphone application.

However, while reminder devices, such as smartphones, are often easily placed elsewhere, such as rooms, bags, suitcases, medical procedures are somewhere else. As a result, these "reminder" devices are useful for certain applications, but are more frequently used in taking some concurrent treatments and forget to receive treatment. Target patients.

Such drug cases are particularly critical to the health of the patient, especially when taking drugs with irregular dosing frequencies, when taking several drugs with different dosing frequencies, especially when underdosing or overdosing. It is used when taking certain medications that may have adverse consequences and when targeting patients who have forgotten to receive treatment.

Even in the primary treatment context, patients taking the drug have significant bias in their prescribed dosing regimen. For major treatments such as rejection therapy and chemotherapy, it is important to remember the previous dose, as regular doses are a key factor in successful treatment.

Regularity is also particularly important in clinical trials.

In both major treatments and clinical trials, it is especially important to be able to identify the causal link between taking the drug and the success of the treatment, the occurrence of side effects, or the lack of efficacy of the treatment, because the causal relationship is This is because it makes it possible to adapt the patient's dose for the primary treatment, or the dose prescribed when the drug under study is marketed. As a result, determining patient compliance with treatment is becoming increasingly important.

In academic research or clinical trials on drug development, measuring the bias of prescribed dosing regimens is the main purpose of electronic devices in drug packages. For induced reminder function, this is often secondary so as not to prejudice the measurement of drug efficacy that is a measurement in a normal population and therefore unaffected by the reminder device. , Or even undesirable. Therefore, some developments have been made to develop electronic devices such that they record when the drug was taken, eg, date and time (or time interval).

Therefore, the data collected by the electronic device corresponding to the time and date of taking each drug not only allows a more accurate assessment of the efficacy and tolerance of treatment, but also allows the patient to, for example, It also allows medical professionals to be notified if they do not follow prescriptions that may affect the patient's health, such as major treatments. In addition, patient compliance with prescriptions allows healthcare professionals to assess on a case-by-case basis whether doses can be adapted.

Therefore, information about medications such as date and time is voluntary action by the patient linked to the patient's own good intentions when reporting medications using an electronic monitoring device that involves mechanical or electronic manipulation. It arises from either from, or from a passively manipulated sensor in an electronic device that records the opening and closing of the drug package and is therefore not linked to the patient's voluntary action.

For example, when a drug package is impacted, dropped to the ground, or inadvertently opened, or the patient inadvertently, for example, inadvertently operates an electronic monitoring device. The detection of false-positive events remains problematic if passively operated electronic monitoring devices inaccurately record events related to drug administration when activated with caution.

Many have tried to solve this problem associated with false positive events. For example, document US7475783 is known from the prior art, which discloses a case for a drug arranged to contain a removable blister pack comprising a series of drugs.
A bottom wall with a first convex outer surface and a second concave inner surface,
A top wall with a first convex inner surface and a second concave outer surface,
Have,
The bottom wall and the top wall have a complementary curved shape to form a case designed to receive the removable blister pack between the bottom wall and the top wall.
The bottom wall and the top wall are at least partially connected to each other on the outer circumference.
The case is
An electron for generating data indicating the taking of the one or more drugs based on the recognition (event capture) (contact recognition) of contact between the connection end of the bottom wall and the connection end of the top wall. A closed end with a monitoring device and
An open end opposite to the closed end for forming a mouth portion between the bottom wall and the top wall designed to insert and / or remove the removable blister pack. Open end and
Have,
The top wall has a first longitudinal notch that forms a first slot from the free end of the top wall opposite the connecting end.

In fact, in this prior art document, the electronic monitoring device is started and stopped when a blister pack with a series of agents is introduced into the case. The electronic monitoring device includes a power supply in the form of a cell or a battery, a sensor, a memory, and optionally a processor. The sensor identifies the installation and / or removal of the blister pack and sends a signal stored in memory. The signal is then processed by the processor to generate data indicating the dose of the drug, if one or more drugs are present.

In the variant, the data is collected and processed by a processor separate from the case, and in some cases the processed data may be reintroduced into the "connected" case by any type of communication means. Therefore, the data indicating the taking of the one or more drugs can be captured events and data (time, date, count), or one processor (or several). It may be more sophisticated data processed by the processor).

The document also discloses that there is an extension on the inner surface of the concave bottom wall that helps prevent the blister pack from being ejected from the case.

Unfortunately, the medicinal cases according to this document have the problematic behavior that when the blister pack is inserted into the case, it is pressed against the inner surface of the bottom wall by the curvature of the case. To remove it, the patient must lift the blister pack with his nails to pass over the extension of the role of preventing drainage, which is then particularly troublesome for the patient or of arthritis or Parkinson's disease. Even impossible in the case of patients with certain diseases such as, they cannot slip out of the case and can cause blister pack deformation during the process of drainage. In fact, the extension should not be too high to allow the blister pack to be removed, but it should prevent the blister pack from being ejected when the case is placed vertically.

The extension cannot properly prevent the blister pack from being ejected from the case once it has to perform two previous functions. In fact, when the drug case is impacted or dropped to the ground, the shock wave moves the blister pack, and the short height of the extension is not enough to prevent the blister pack from being ejected from the case. Yes, this causes a false positive event detected by the electronic monitoring device as the blister pack moves from its position.

Attempts have been made to resolve this problem associated with false-positive events, but the fact remains that this problem still exists in current drug cases that need to be ameliorated.

Therefore, the electronic monitoring device of the case is reliable in capturing information about taking the drug, especially in solving the problem of detecting false positive events and reducing the deformation of the blister pack when removed from the case. Certain drug cases are generally needed. In fact, pharmaceutical cases must be easy for patients to use and mass-produced, taking into account assembly, cost, or material recycling constraints.

An object of the present invention is
(I) The bottom wall has a second notch at the open end of the case that forms a second slot from the free end on the side opposite to the connection end, and the first slot. And the second slot, one of which is superposed on the other, at the open end of the case to form the mouth.
(Ii) The bottom wall includes at least two protrusions having a height greater than the thickness of the blister pack, each of which is located on either side of the second slot and from the inner surface to the top wall. Prolonged towards
(Iii) The top wall has at least two lateral walls that are substantially parallel in the longitudinal direction, each of the two lateral walls being arranged on both sides of the first slot, and the at least two lateral walls. Extending from the inner surface of the top wall toward the bottom wall,
It is to solve the above-mentioned problem by providing the drug case mentioned at the beginning, which is characterized by the above.

In fact, advantageously, according to the invention, for a drug case or secondary package for a drug with a second slot at the free end of the bottom wall overlaid with the first slot on the top wall. The case allows the first finger to be inserted into the slot on the top wall and the second finger to be inserted into the slot on the bottom wall, thus allowing the patient to grip the blister pack. It is possible to grip the blister pack between two fingers so that it can be removed from the case by lifting the part and then sliding it (sliding, sliding) from the case. It was revealed that the deformation of the blister pack was reduced during the removal process.

According to the present invention, the presence of two protrusions (protrusions, lugs) (lugs), each placed on either side of a slot in the bottom wall and extending towards the top wall, is a blister pack at the position inserted into the case. Makes it possible to block reliably.

Further, according to the present invention, the fact that the apex wall comprises at least two side walls that are substantially parallel in the longitudinal direction and each located on either side of the apex wall slot towards the bottom wall. The blister pack can be placed on the bottom wall without interfering with the removal of the blister pack as facilitated by the stacked slots for inserting two fingers that allow the patient to pinch the blister pack to remove the blister pack. On the other hand, it is possible to hold it in that position and in contact with the two protrusions.

In fact, the present invention preferably holds the blister pack when the blister pack is inserted into the case to place the blister pack in a position where the concave curvature of the bottom and top walls is detected by an electronic monitoring device. It makes it possible to offer medicinal cases in an advantageous way, which makes it possible to strengthen things. The presence of at least two lateral walls allows the blister pack to be pressed and held against the bottom wall. The two protrusions provide accurate positioning of the blister pack at the position of the blister pack within the case, as detected by the electronic monitoring device. This reduces false positive events. Therefore, the two protrusions that allow the blister pack to be held in this position are provided, for example, during an impact or when the drug case falls, even if the case provided with the blister pack suddenly moves. Sometimes reduce the detection of false positive events. As a result, the quality of event capture associated with drug administration is improved. Finally, the bottom wall-placed slot, which overlaps the top wall-placed slot, allows the patient to easily grip the blister pack while preserving the reliability of event capture. It is possible to reduce the deformation of the blister pack, which acts with ease of grip, and reduce the occurrence of false positive events, because not deforming the blister pack causes the blister pack to accidentally fall into the case. Prevent accidental removal of the blister pack by preventing it from being deployed and avoiding multiple attempts to properly deploy the blister pack in the contact position captured by the electronic monitoring device. This is because it allows the two protrusions to be cleverly placed on both sides of the slot at a height sufficient for the blisters.

In a preferred embodiment according to the invention, the at least two protrusions extend along a first plane having an intersection with a second plane in contact with the bottom wall, on which the center of the trigonometric marker is lateral. Positioned in the direction, the cosine axis is inscribed in the second plane, and the first plane forms an inclination angle of the at least two protrusions with the tangent second plane and is inclined. The angle has a sine of 0.5 or more, or even 0.7 or more, preferably 0-0.5, preferably 0-0.3 cosine.

In fact, this extension allows at least two protrusions to block the blister pack in the case, thus detecting false positive events that can occur during impact or while the drug case falls. To reduce. When the cosine is 0-0.5, more specifically 0-0.3, it is easy to take out, the deformation is reduced, and the production is easy.

In fact, such cases are preferably manufactured by injection molding. The orientation of at least two protrusions facilitates mold release and thus avoids deterioration of parts that can cause damage to the protrusions during mold release.

In the modifications according to the invention, the at least two protrusions are at least 0.3 mm, preferably at least 0.6 mm, preferably at least 0.8 mm, particularly preferably at least 1.0 mm, preferably at least 1.2 mm. It preferably has a height of at least 1.4 mm, preferably at least 1.6 mm.

In fact, at least two protrusions allow the patient to lift the blister pack to remove the blister pack by sliding the blister pack over the at least two protrusions (sliding, sliding). Can be accurately positioned within the case to prevent accident-related false positive events in the handling of the case.

Advantageously, the at least two lateral walls are designed to partially force contact of the blister pack with respect to the bottom wall, the contact being visible through the mouth with respect to the total surface area of the blister pack. Starting from the end of the blister pack on the opposite side, row over the surface area of at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90% of the blister pack. Be blistered.

In fact, the blister pack is mounted on the bottom wall by having at least two lateral walls designed to force the blister pack into contact with the bottom wall over a large surface area starting from the end of the blister pack detected by the electronic monitoring device. In contrast, it holds in place for at least two protrusions, allowing for reliable contact with the electronic monitoring device, thereby preventing false positive events, while the blister pack is electronic. It contributes to guiding the blister pack to be detected by the monitoring device and also reduces the deformation of the blister pack.

In another preferred embodiment according to the invention, the at least two lateral walls have a first longitudinal ridge (ridge, ridge, ridge, ridge), a second longitudinal ridge and two lateral ridges. The first lateral ridge is located near the closed end of the case and the second lateral ridge is located at the open end of the case and extends between the two longitudinal ridges. The second transverse ridge has a longer length than the first transverse ridge, and the first longitudinal ridge in contact with the inner surface of the apex wall is said to be said. It is longer than the second longitudinal ridge, which is opposite the first longitudinal ridge and is substantially parallel to the first longitudinal ridge.

In fact, the second lateral ridge may be rounded, parabolic, oval, or beveled. Thus, the two lateral walls form a recess at the open end, which allows the patient to grip the blister pack with two fingers through a slot on the bottom and a slot on the top and the blister pack. The blister pack facilitates passage of the blister pack when it is desired to be removed from the case by lifting and sliding the blister pack out of the case according to the invention above at least two protrusions. Reduce the deformation of. In addition, the second lateral ridge allows the blister pack to be guided as it is introduced into the mouth of the case, and the lateral wall between the inner surface of the bottom wall and the second longitudinal ridge. Allows you to make it slippery underneath.

The second lateral ridge also makes it possible to reduce the friction phenomenon between the blister pack and the at least two lateral walls. In fact, when the blister pack is removed by the patient, the blister pack is lifted to pass through at least two protrusions and to be removed from the case. The second lateral ridge reduces friction between the blister pack and the lateral wall, reducing lateral damage and deformation of the blister pack.

Advantageously, the length of the first longitudinal ridge is at least 5 mm, preferably at least 10 mm, more specifically at least 15 mm, at most 30 mm, preferably at most, than the length of the second longitudinal ridge. 25 mm, more specifically at most 20 mm longer.

As a result, according to the present invention, in the pharmaceutical case, a first space is formed between the inner surface of the bottom wall and each of the at least two lateral walls, and the inner surface of the bottom wall and the second side wall are formed. The shortest distance to the longitudinal ridge is at least 0.4 mm, preferably at least 0.6 mm, preferably at least 0.8 mm, particularly preferably at least 1.0 mm, preferably at least 1.2 mm, preferably at least 1.2 mm. It is at least 1.4 mm, preferably at least 1.6 mm, at most 3.0 mm, preferably at most 2.6 mm, preferably at most 2.2 mm, and preferably at most 1.8 mm.

Advantageously, according to the invention, in a pharmaceutical case, a second space is formed between the at least two protrusions and the second lateral ridge of each of the at least two lateral walls, at least two. The shortest distance between any point on the protrusion and the second lateral ridge of at least two lateral walls is at least 0.3 mm, preferably at least 0.4 mm, preferably at least 0.5 mm, preferably at least 0. 6.6 mm, preferably at least 0.7 mm, particularly preferably at least 0.8 mm, especially at least 0.9 mm and at most 2.0 mm, preferably at most 1.8 mm, preferably at most 1.6 mm, preferably At most 1.4 mm, preferably at most 1.2 mm.

In another preferred embodiment according to the invention, the electronic monitoring device further comprises a processor and optionally a display device, preferably an LCD screen, which processes the captured event to one or more of the above. Designed to transmit said data indicating taking the drug, the data is optionally displayed on the display device, especially for notifying the patient that the drug was actually taken. Are suitable.

In another variant of the invention, the electronic monitoring device comprises a memory designed to record the date and time of the captured event.

Advantageously, according to the present invention, the pharmaceutical case may be made of one or more materials independently selected from the group consisting of wood, cardboard, paper, plastics, metals and polymers.

In a preferred embodiment, the pharmaceutical case of the present invention further comprises a system for blocking the removal of removable blister packs designed to prevent opening by children.

Other embodiments of the pharmaceutical case are set forth in the appended claims.

The present invention also relates to the use of a drug case for a drug to determine a patient's compliance with a prescribed dose.

In fact, having a pharmaceutical case according to the invention proved to be advantageous for studying patient compliance with prescribed doses.

Other forms of use of the pharmaceutical case are set forth in the appended claims.

Hereinafter, the present invention will be described in more detail with reference to the accompanying drawings.

The top view of the drug case according to this invention which does not have a display device and does not have a blister pack is shown. The top view of the pharmaceutical case according to this invention which has a display device and a blister pack is shown. The bottom view of the drug case according to this invention which does not have a blister pack and has a mounting screw is shown. The bottom view of the drug case according to the present invention which has a blister pack and does not have a mounting screw is shown. It is a side view of the drug case by this invention. It is a rear view of the closed end portion of the pharmaceutical case according to this invention. A front view of an open end of a pharmaceutical case according to the present invention without a blister pack is shown. A front view of an open end of a pharmaceutical case according to the present invention having a blister pack is shown. It is a partial cross-sectional view of the pharmaceutical case according to this invention along the line AA of FIG. 1b.

The same or similar elements have the same reference numerals on the drawings.

1a and 1b show a pharmaceutical case 1 according to the invention designed to accommodate a removable blister pack 2 with a series of medications 3. The drug case 1 has a first outer surface 5 and a second inner surface 6, a radius of curvature ≤ 0, preferably a concave (upward concave) bottom wall 4, a first inner surface 8 and a second outer surface 9. It is provided with a top wall 7 having a radius of curvature ≦ 0, preferably a concave shape (upward concave surface).

The first outer surface 5 of the bottom wall 4 is convex, and the second inner surface 6 of the bottom wall 4 is concave.

The first inner surface 8 of the top wall 7 is convex, and the second outer surface 9 of the top wall 7 is convex.

For the purposes of the present invention, the term "concave" is intended to mean a hollow surface that is inwardly rounded in shape.

For the purposes of the present invention, the term "convex" is intended to mean a bulging surface that has an outwardly rounded shape.

The bottom wall 4 and the top wall 7 have a complementary curved shape to form a case 1 designed to receive a removable blister pack 2 between the bottom wall 4 and the top wall 7. The wall 4 and the top wall 7 are at least partially connected to each other on the outer circumference.

The case 1 has a closed end 11 that contacts the connecting end of the bottom wall 4 and the connecting end of the top wall 7 on the one hand, and an open end that forms a mouth portion opposite to the closed end 11 on the other hand. A unit 12 is provided. The periphery of the mouth is in contact with the free end of the bottom wall 4 and the free end of the top wall 7.

The closed end 11 of the case 1 is provided with an electronic monitoring device 13 that makes it possible to generate data indicating drug administration based on event capture. The open end 12 forms a mouth designed to insert and / or remove a removable blister pack 2 between the bottom wall 4 and the top wall 7.

The top wall 7 has a first longitudinal notch that forms a first slot 14 from the free end of the top wall 7.

The bottom wall 4 has a second longitudinal notch that forms a second slot 15 from the free end of the bottom wall 4 at the open end 12 of the case 1.

One of the first slot 14 and the second slot 15 is superposed on the other, forming a mouth portion at the open end of the case 1.

In fact, the first slot 14 and the second slot 15 are superposed on each other and the first finger is passed through the first slot 14 in order to remove the patient-removable blister pack 2 from the drug case 1. , By passing the second finger through the second slot 15, it is possible to grip the removable blister pack 2.

In a preferred embodiment of the invention, the electronic monitoring device 13 located on the case 1 comprises a sensor, a memory capable of recording the date and time of a captured event, a processor, and a display device 16. The display device 16 is preferably an LCD screen. The processor is designed to process the captured event and transmit a signal containing data indicating drug intake, which data is optionally displayed on the display device 16 of the electronic monitoring device 13. Can be done.

In fact, the sensor identifies the introduction and / or removal of the removable blister pack 2. When the patient inserts the removable blister pack 2 into the case 1, the sensor of the electronic monitoring device 13 detects the end of the blister pack, for example by contact, and the patient takes out the removable blister pack 2 and takes the drug. Then, the contact between the end of the blister pack and the sensor of the electronic monitoring device 13 is broken. The sensor transmits a signal stored in memory, which is processed by the processor to generate data indicating the taking of the one or more medications. The indicated event and data may be time, date, or count, or more elaborate data processed by one or more processors. These event and display data are collected and processed in a processor separate from the drug case 1, or, if any, the event or display data is connected by any type of communication means. It may be reintroduced into the drug case 1.

2a and 2b have no removable blister pack 2 (FIG. 2a) and have removable blister packs (FIG. 2b) from the outer surface 5 of the bottom wall 4 and the free end of the bottom wall 4. The bottom view of the drug case 1 which shows the 2nd slot 15 is shown.

In fact, the end of the removable blister pack 2 visible through the mouth between the first slot 14 and the second slot 15 stacked at the top of each other is the patient removable blister pack 2. Pinch this end of the blister to allow it to be removed from the drug case 1.

FIG. 3 shows a side view of the drug case 1 having a first outer surface 5 of the bottom wall 4 and a second outer surface 9 of the top wall 7, and these outer surfaces are at least partially connected to each other on the outer circumference. Has been done.

FIG. 4 shows the closed end 11 of the drug case 1 in contact with the connecting end of the bottom wall 4 and the connecting end of the top wall 7.

The connection end of the bottom wall 4 and the connection end of the top wall 7 are manufactured by injection molding, for example, and the closed end 11 of the case 1 is the connection end of the bottom wall 4 and the connection end of the top wall 7. Is obtained by sandwiching it on the outer circumference.

5a and 5b show a view of the open end 12 of the drug case 1 in which the free end of the bottom wall 4 and the free end of the top wall 7 are visible. The open end 12 forms the mouth of the case 1 using the first slot 14 of the top wall 7 and the second slot 15 of the bottom wall 4.

The bottom wall 4 includes at least two protrusions 17 arranged on both sides of the second slot 15 and extending from the inner surface 6 of the bottom wall 4 toward the top wall 7.

In fact, at least two protrusions 17 help hold the removable blister pack 2 when inserted into the drug case 1. The presence of at least two protrusions 17 that are higher than the thickness of the removable blister pack 2 allows the removable blister pack 2 to be present even when the drug case 1 is impacted or accidentally dropped. Allows you to stay in that insertion position.

In a preferred embodiment of the invention, the at least two protrusions 17 are at least 0.3 mm, preferably at least 0.6 mm, preferably at least 0.8 mm, particularly preferably at least 1.0 mm, preferably at least 1.2 mm. , Advantageously having a height of at least 1.4 mm, preferably at least 1.6 mm.

The apex wall 7 includes at least two lateral walls 18 extending substantially parallel to the longitudinal direction l of the drug case 1. At least two side walls 18 are arranged on both sides of the first slot 14 and extend from the first inner surface 8 of the top wall 7 toward the bottom wall 4.

In fact, at least two side walls 18 allow the removable blister pack 2 to be held in its position with respect to the bottom wall 4 and in contact with the two protrusions 17.

In a preferred embodiment of the invention, at least two lateral walls 18 are arranged to partially force contact of the removable blister pack 2 with the bottom wall 4. The contact of the removable blister pack 2 is relative to the total surface area of the removable blister pack 2 of the surface area starting from the end of the blister pack opposite to being visible through the mouth of the case 1. It is carried out over a surface area of at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%.

In fact, at least two side walls 18 for the bottom wall 4 and at least two protrusions 17 to properly hold the blister pack 2 in that position inserted in the case 1 over a large area. It allows the removable blister pack 2 to be forced into contact with the bottom wall 4, thereby ensuring contact with the electronic monitoring device 13 to prevent false positive events, while ensuring that it is in contact with the electronic monitoring device 13. It contributes to guiding the blister pack throughout its entry into the drug case 1 and reduces deformation of the blister pack so that the removable blister pack 2 is detected by the electronic monitoring device 13.

FIG. 6 shows a removable blister pack 2, a convex outer surface 5 and a concave inner surface 6 of the bottom wall 4, a convex inner surface 8 and a concave outer surface 9 of the top wall 7, at least two protrusions 17, and at least two. FIG. 5 is a cross-sectional view of the pharmaceutical case 1 according to the present invention along the line AA from FIG. 1b, showing the side wall 18 and the side wall 19 of the case 1.

In fact, the removable blister pack 2 at its inserted position in the drug case 1 abuts at least two protrusions 17 so that it is blocked at a position where it contacts the electronic monitoring device 13. ing. The presence of at least two side walls 18 allows the removable blister pack 2 to be held in that position relative to the bottom wall 4 and thus in the correct position with the electronic monitoring device 13 so that the drug case 1 can be impacted or dropped. Reduce the detection of false positive events in.

While removing the removable blister pack 2 from the case 1, the patient is at the end of the removable blister pack 2 accessible between the first slot 14 on the top wall 7 and the second slot 15 on the bottom wall 4. The portion is pinched and then the removable blister pack 2 is lifted above at least two protrusions 17 and slid out of the drug case 1. When the removable blister pack 2 is removed from the case 1, contact with the electronic monitoring device 13 is broken and the electronic monitoring device 13 captures events related to drug administration.

Further, in a particular embodiment of the invention, at least two protrusions 17 extend along a first plane having an intersection with a second plane in contact with the bottom wall 4, a trigonometric marker on the intersection. The center of the is laterally positioned, its cosine axis is inscribed in the second plane, and the first plane has an inclination angle of at least two protrusions 17 with the second plane in contact. It forms and has a tilt angle of 0.5 or more or even 0.7 or more sine, preferably 0-0.5, preferably 0-0.3 cosine.

In this way, at least two protrusions 17 allow the removable blister pack 2 to be blocked inside the drug case 1, which reduces the detection of false positive events, while cosine. When is 0-0.5, more specifically 0-0.3, it is easy to remove the removable blister pack from the drug case 1, and the removable blister pack 2 Reduce deformation.

In fact, such a pharmaceutical case 1 according to the present invention is preferably manufactured by injection molding. The orientation of at least two protrusions 17 facilitates mold release and thus avoids deterioration of parts that cause damage to the protrusions 17 during mold release.

According to another embodiment of the present invention, at least two lateral walls 18 have a first longitudinal ridge 20, a second longitudinal ridge 21, and two lateral ridges 22, 23. The first lateral ridge 22 is located near the closed end 11 of the case 1. The second lateral ridge 23 is located near the open end 12 of the case 1 and forms a free ridge extending between the two longitudinal ridges 20, 21. Further, the second horizontal ridge 23 has a length longer than the length of the first horizontal ridge 22.

Further, the first longitudinal ridge 20 in contact with the inner surface 8 of the top wall 7 is a second longitudinal ridge opposite the first longitudinal ridge 20 and substantially parallel to the first longitudinal ridge. It has a length of at least 5 mm, preferably at least 10 mm, more specifically at least 15 mm, at most 30 mm, preferably at most 25 mm, and more specifically at most 20 mm longer than the directional ridge 21.

In fact, the second lateral ridge 23 may thus be rounded, parabolic, elliptical, or beveled to the pharmaceutical case 1. It can facilitate the passage of the removable blister pack 2 during introduction and / or removal from the drug case 1.

In a preferred embodiment of the present invention, a first space 24 is formed between the inner surface 6 of the bottom wall 4 and each of at least two lateral walls 18, and the inner surface 6 of the bottom wall 4 and the second longitudinal ridge 21 are formed. The shortest distance to and from is at least 0.4 mm, preferably at least 0.6 mm, preferably at least 0.8 mm, particularly preferably at least 1.0 mm, preferably at least 1.2 mm, preferably at least 1. It is 4 mm, preferably at least 1.6 mm, at most 3.0 mm, preferably at most 2.6 mm, preferably at most 2.2 mm, and preferably at most 1.8 mm.

In a modification of the present invention, a second space 25 is formed between at least two protrusions 17 and each second lateral ridge of at least two lateral walls 18, at least at any point on the at least two protrusions and at least. The shortest distance between the two lateral walls to the second lateral ridge is at least 0.3 mm, preferably at least 0.4 mm, preferably at least 0.5 mm, preferably at least 0.6 mm, preferably at least 0. .7 mm, particularly preferably at least 0.8 mm, especially at least 0.9 mm and at most 2.0 mm, preferably at most 1.8 mm, preferably at most 1.6 mm, preferably at most 1.4 mm, advantageously Is at most 1.2 mm.

In a preferred embodiment of the invention, the pharmaceutical case 1 can be made of one or more materials such as wood, cardboard, paper, plastics, metals, polymers and the like.

In addition, Pharmaceutical Case 1 is used to determine a patient's compliance with a prescribed dose.

For example, according to the present invention, in the pharmaceutical case 1, at least two side walls 19, the bottom wall 4, and the at least two protrusions 17 slide (slide and slide) in the case 1. It is conceivable to form a drawer that can be received.

The two protrusions can form, among other things, the front surface of the drawer.

In this case, the concave surface of the case can be characterized by a radius of curvature of ≤ 0, which means that the drug case is arranged to accommodate a removable blister pack with a series of drugs.
A bottom wall (4) having a radius of curvature ≤ 0 with a first outer surface (5) and a second inner surface (6),
A top wall (7) having a radius of curvature ≤ 0 with a first inner surface (8) and a second outer surface (9),
Have,
The bottom wall (4) and the top wall (7) are such that the removable blister pack (2) is received between the bottom wall (4) having a radius of curvature ≤ 0 and the top wall (7). Designed complementary shape,
The bottom wall (4) and top wall (7) are at least partially connected to each other on the outer circumference.

Of course, the present invention is not limited to the above-described embodiment, and many modifications can be made without departing from the scope of the appended claims.

Claims (14)

A drug case (1) designed to contain a removable blister pack (2) that houses a series of drugs (3).
The drug case (1) is
A bottom wall (4) having a first convex outer surface (5) and a second concave inner surface (6),
A top wall (7) having a first convex inner surface (8) and a second concave outer surface (9),
Have,
The bottom wall (4) and the top wall (7) are designed to accommodate the removable blister pack (2) between the bottom wall (4) and the top wall (7). It has a curved shape that is complementary to form 1).
The bottom wall (4) and the top wall (7) are at least partially connected to each other on the outer circumference.
The case (1) is
To generate data indicating taking one or more of the drug (3) based on the recognition of contact with the connecting end of the bottom wall (4) and the connecting end of the top wall (7). A closed end (11) with an electronic monitoring device (13) and
The removable blister pack (2) is inserted between the bottom wall (4) and the top wall (7) at the open end (12) opposite to the closed end (11). / Or an open end (12) forming a mouth designed to be removed,
Have,
The top wall (7) has a first longitudinal notch that forms a first slot (14) from the free end of the top wall (7) opposite the connection end.
In the drug case
(I) The bottom wall (4) forms a second slot (15) from the free end on the open end (12) of the case (1) opposite to the connection end. The first slot (14) and the second slot (15), one of which is superposed on the other, at the open end (12) of the case (1). Form the mouth,
(Ii) The bottom wall (4) includes at least two protrusions (17) having a height greater than the thickness of the blister pack (2), each arranged on either side of the second slot (15). And extends from the inner surface (6) toward the top wall (7).
(Iii) The top wall (7) has at least two side walls (18) substantially parallel to the longitudinal direction (l), and each of the two side walls (18) has the first slot (1). For pharmaceutical use, the at least two lateral walls (18) arranged on both sides of the 14) extend from the inner surface (8) of the top wall (7) toward the bottom wall (4). Case (1). The at least two protrusions (17) extend along a first plane having an intersection with a second plane in contact with the bottom wall (4), and the center of the trigonometric marker extends laterally on the intersection. The cosine axis is inscribed in the second plane, and the first plane forms an inclination angle of the at least two protrusions (17) with the second plane in contact with the second plane. The inclination angle is characterized by having a sine of 0.5 or more, more preferably 0.7 or more, and preferably having a cosine of 0 to −0.5, preferably 0 to −0.3. The pharmaceutical case (1) according to claim 1. The at least two protrusions (17) are at least 0.3 mm, preferably at least 0.6 mm, preferably at least 0.8 mm, particularly preferably at least 1.0 mm, preferably at least 1.2 mm, preferably at least at least. The pharmaceutical case (1) according to claim 1 or 2, characterized in that it has a height of 1.4 mm, preferably at least 1.6 mm. The at least two lateral walls (18) are arranged to partially force contact of the blister pack (2) with respect to the bottom wall (4).
The contact is
At least 50%, preferably at least 60%, preferably at least 70% of the blister pack, advantageous, with respect to the total surface area of the blister pack, starting from the end of the blister pack opposite to what is visible through the mouth. The pharmaceutical case (1) according to any one of claims 1 to 3, wherein the treatment is carried out over a surface area of at least 80%, preferably at least 90%. The at least two lateral walls (18) have a first longitudinal ridge (20), a second longitudinal ridge (21) and two lateral ridges (22, 23).
The first lateral ridge (22) is located near the closed end (11) of the case (1).
The second lateral ridge (23) is located at the open end (12) of the case (1) and forms a free ridge extending between the two longitudinal ridges (20, 21). Further, the second horizontal ridge (23) has a longer length than the first horizontal ridge (22).
The first longitudinal ridge (20) in contact with the inner surface (8) of the top wall (7) is opposite to the first longitudinal ridge (20) and is in the first longitudinal direction. The pharmaceutical case (1) according to any one of claims 1 to 4, characterized in that it is longer than the second longitudinal ridge (21) that is substantially parallel to the ridge (20). The length of the first longitudinal ridge (20) is at least 5 mm, preferably at least 10 mm, more specifically at least 15 mm, at most 30 mm, than the length of the second longitudinal ridge (21). The pharmaceutical case (1) according to claim 5, characterized in that it is preferably at most 25 mm, more specifically at most 20 mm longer. A first space (24) is formed between the inner surface (6) of the bottom wall (4) and each of the at least two lateral walls (18).
The shortest distance between the inner surface (6) of the bottom wall (4) and the second longitudinal ridge (21) is at least 0.4 mm, preferably at least 0.6 mm, preferably at least 0.8 mm. Particularly advantageously at least 1.0 mm, preferably at least 1.2 mm, preferably at least 1.4 mm, preferably at least 1.6 mm, at most 3.0 mm, preferably at most 2.6 mm, preferably at most The pharmaceutical case (1) according to any one of claims 1 to 6, characterized in that it is 2.2 mm, preferably at most 1.8 mm. A second space (25) is formed between the at least two protrusions (17) and the second lateral ridge (23) of each of the at least two lateral walls (18).
The shortest distance between any point on the at least two protrusions (17) and the second lateral ridge (23) of the at least two lateral walls (18) is at least 0.3 mm, preferably at least 0. 4 mm, preferably at least 0.5 mm, preferably at least 0.6 mm, preferably at least 0.7 mm, particularly preferably at least 0.8 mm, especially at least 0.9 mm and at most 2.0 mm, preferably at most The agent according to any one of claims 1 to 7, characterized in that it is 1.8 mm, preferably at most 1.6 mm, preferably at most 1.4 mm, and preferably at most 1.2 mm. Case (1). The electronic monitoring device (13) further includes a processor and optionally a display device (16), preferably an LCD screen.
The processor is designed to process captured events and transmit the data indicating taking one or more of the drugs.
The pharmaceutical case (1) according to any one of claims 1 to 8, wherein the data is optionally displayed on the display device (16). The pharmaceutical case according to any one of claims 1 to 9, wherein the electronic monitoring device (13) includes a memory designed to record the date and time of a captured event. (1). Any one of claims 1-10, characterized in that it may be made of one or more materials independently selected from the group consisting of wood, cardboard, paper, plastics, metals and polymers. The pharmaceutical case (1) according to. 1. A aspect of claim 1, wherein at least two side walls (19), the bottom wall (4) and the at least two protrusions (17) form a drawer that can be slid into the case (1). The pharmaceutical case (1) according to any one of 11. 12. The medicinal case (1) of claim 12, further comprising a system for blocking said slippery drawers designed to prevent children from opening. Use of the pharmaceutical case (1) according to any one of claims 1 to 13 to determine a patient's compliance with a prescribed dose.

Images